Objectives: One of the primary antiatherogenic properties of HDL is its role in promoting reverse cholesterol transport (RCT). The capacity of serum HDL to promote efflux of cholesterol from cells (cholesterol efflux capacity, CEC) represents an index of HDL functionality and its evaluation serves to estimate the efficiency of the entire process in humans. It has been suggested that HDL functionality changes may contribute to cardiovascular disease protection. Inflammation is a central feature during all stages of atherosclerotic plaque formation with cytokines/chemokines orchestrating the influx of immune cells in disease vessels. Indeed, systemic inflammatory diseases have been associated with an increased cardiovascular risk. The objective of this study was to analyze whether acute systemic inflammatory disease may affects the capacity of HDL to promote cholesterol efflux through the main pathways, (aqueous diffusion (AD), the scavenger receptor-BI (SR-BI) and the ATP binding cassette transporters A1 (ABCA1) and G1 (ABCG1)).
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2014 Published by Elsevier Inc.